PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in PAD treatment

Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at VEITHsymposium 2018.